Catalyst Event
SK Biopharmaceuticals Co Ltd (326030) · Earnings Release
From KRX Bio Technology Transfer Index (KBIOTT)
5/7/2026, 12:00:00 AM
SK Biopharmaceuticals announced record Q1 2026 results on May 7, 2026, with revenue of KRW 227.9 billion (+57.8% YoY) and an operating profit of KRW 89.8 billion (+249.7% YoY), significantly exceeding market expectations, expected. High impact estimated due to the significant earnings surprise.
Korean Translation
2026년 5월 7일, 2026년 1분기 매출 2279억원 및 영업이익 898억원으로 시장 기대치를 크게 상회하는 실적 발표가 예상됨. 어닝 서프라이즈에 따른 높은 주가 영향이 예상됨.
Related Recent Events
SK Biopharmaceuticals Co Ltd (326030) · Other
SK Biopharmaceuticals is scheduled to be removed from the MSCI Korea Index effective at the close of May 29, 2026, following an announcement on May 12, 2026, which may lead to passive fund outflows, scheduled. Medium impact estimated due to expected passive fund outflows.
5/29/2026, 12:00:00 AM
LigaChem Biosciences Inc (141080) · Earnings Release
Q1 2026 earnings release on 2026-05-18 with high price impact expected based on results versus expectations scheduled.
5/18/2026, 12:00:00 AM
Voronoi Inc (310210) · Other
Corporate briefing (IR) for domestic and international institutional investors to explain company status scheduled; 1% price impact as IR sessions typically have limited immediate market reaction analysts estimated.
5/18/2026, 12:00:00 AM
OliX Pharmaceuticals Inc (226950) · Other
CEO Dong Ki Lee is scheduled to present research on the company's RNAi platform for ophthalmic diseases at the TIDES USA 2026 conference on May 14, 2026; a 5% price impact is estimated due to potential clinical data updates, scheduled.
5/14/2026, 12:00:00 AM
HK inno N Corporation (195940) · Other
Announced on May 13, 2026, that its blockbuster drug 'K-CAB' became the top-prescribed drug in Korea for April 2026, with monthly outpatient prescription sales of KRW 20.8 billion.
5/13/2026, 12:00:00 AM
Daewoong Pharmaceutical Co Ltd (069620) · Earnings Release
Daewoong Pharmaceutical announced its Q1 2026 earnings on May 12, 2026. On a separate basis, revenue was KRW 335.7 billion (+6.2% YoY) while operating profit was KRW 27.4 billion (-34.7% YoY).
5/12/2026, 12:00:00 AM